Leveraged Finance Industry Gathers to Fight Melanoma at Fifth Annual Benefit

Event Set for May 24 in New York City

NEW YORK–(BUSINESS WIRE)–The leveraged finance community will gather for the fifth annual
Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party with
the goal of raising funds to support the Melanoma Research Alliance
(MRA), the world’s largest private funder of melanoma research. Melanoma
is the deadliest form of skin cancer, and MRA is dedicated to fighting,
treating, and curing melanoma.

The event will be hosted by Brendan Dillon of UBS; Lee Grinberg of
Elliott Management; George Mueller and Cade Thompson of KKR; Jeff
Rowbottom of PSP Investments; and Trevor Watt of Hellman & Friedman.

The event will be held from 6:00-9:00pm on Tuesday, May 24 at the Summer
Garden at Rockefeller Plaza.

Event attendees will include leaders from throughout the industry, and
dealmakers from banks, investment firms, law firms, issuers and
sponsors, with over 1,000 expected to attend.

Since the inaugural event in 2012, the leveraged finance community has
raised over $5 million to support MRA’s global research programs,
working toward eliminating suffering and death from melanoma. Tickets
are $300 and may be purchased by visiting www.curemelanoma.org/LFFM.

The event seeks to raise funds to advance research and educate attendees
on the dangers of melanoma and the importance of sun safety and early
detection. If melanoma is found early—before it has spread beyond the
skin—it is almost always treatable. Past events have led to attendees
scheduling skin checks and even to the discovery and treatment of
several early-stage melanomas.

Recent landmark advances in melanoma treatments have provided new
options for patients, and melanoma stands as the case study for
state-of-the-art cancer drug development, precision medicine and
immunotherapy. The data that melanoma scientists are generating is also
benefiting cancer researchers in many fields, including those studying
bladder, brain, breast, colon, kidney, leukemia, lymphoma, lung,
pancreatic, and prostate cancer.

Nearly 80,000 Americans will be diagnosed with melanoma in 2016—roughly
one person every eight minutes, and incidence of the disease continues
to rise. The skin disease is the fifth most common cancer diagnosed in
the United States. While the treatment outlook for the disease has
improved in recent years, newly approved therapies will not be the cure
for most patients, so continuing to support research is critical.

About The Melanoma Research Alliance (MRA)

MRA is a public charity formed in 2007 under the auspices of the Milken
Institute, with the generous founding support of Debra and Leon Black.
MRA to date has dedicated more than $68 million to research seeking to
better prevent, diagnose, and treat melanoma. Due to the ongoing support
of its founders, 100% of every dollar MRA raises goes to support its
melanoma research program. The organization is poised to build on recent
momentum in the field, accelerating the pace of scientific discovery and
translation in order to eliminate suffering and death due to melanoma.
MRA’s ability to fund wide-ranging research in melanoma is amplified by
unique multi-faceted collaborations with individuals, private
foundations and corporations.

For more information on MRA, visit www.CureMelanoma.org.

Contacts

Anreder & Company:
212-532-3232
Steven S. Anreder
steven.anreder@anreder.com
or
Michael
Wichman
michael.wichman@anreder.com